生物制剂治疗白塞病葡萄膜炎:一项系统综述
该系统综述检索截至2018年10月16日的文献,从237篇文献中纳入8项随机对照试验,涉及干扰素α2a、阿达木单抗、司库奇尤单抗、gevokizumab、利妥昔单抗和达珠单抗。司库奇尤单抗、达珠单抗和gevokizumab未达到结局指标,利妥昔单抗和干扰素α2a显示初步 promising 结果但需足够把握度的随机对照试验,阿达木单抗的随机对照试验未专门评估白塞病葡萄膜炎疗效。结论认为部分生物制剂有前景,但需更多随机对照试验才能得出确切疗效结论。
要点
- 从237篇文献中纳入8项随机对照试验,涉及6种生物制剂。
- 司库奇尤单抗、达珠单抗和gevokizumab的随机对照试验未达到结局指标。
- 利妥昔单抗和干扰素α2a显示初步 promising 结果,但需足够把握度的随机对照试验提供疗效证据。
核心结论
- 部分生物制剂在治疗白塞病葡萄膜炎中显示前景,但需要更多随机对照试验才能得出确切疗效结论。
- 一项IV期研究或阿达木单抗登记研究可提供其与其他剂型比较治疗白塞病葡萄膜炎疗效的数据。
研究设计与样本
- 系统综述,检索MEDLINE、Cochrane图书馆、效果评价摘要数据库、ClinicalTrials.gov、Science Direct和Google Scholar,无地区、语言或日期限制,检索更新至2018年10月16日。
- 文献检索限制为生物制剂的随机对照试验,共检索到237篇文献,其中8篇符合纳入标准。
主要发现
- 纳入的随机对照试验涉及干扰素α2a、阿达木单抗、司库奇尤单抗、gevokizumab、利妥昔单抗和达珠单抗,其中阿达木单抗和gevokizumab各有两项。
- 司库奇尤单抗、达珠单抗和gevokizumab的随机对照试验未达到结局指标。
- 利妥昔单抗和干扰素α2a显示初步 promising 结果,但需要足够把握度的随机对照试验提供充分的疗效证据。
- 阿达木单抗的随机对照试验未专门评估白塞病葡萄膜炎的疗效,因此对本综述价值有限。
关键数值与推荐
- 结局指标在司库奇尤单抗、达珠单抗和gevokizumab的随机对照试验中未达到。
- 利妥昔单抗和干扰素α2a显示初步 promising 结果,但需要足够把握度的随机对照试验提供充分的疗效证据。
临床怎么用
- 原文未据此给出推荐。
局限性
- 证据基础有限,多来自葡萄膜炎和白塞病表现的研究。
- 利妥昔单抗和干扰素α2a的初步结果需要足够把握度的随机对照试验提供充分的疗效证据。
- 阿达木单抗的随机对照试验未专门评估白塞病葡萄膜炎的疗效,对本综述价值有限。
- 需要更多随机对照试验才能得出确切疗效结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biologics are increasingly used in management of Behçet's Disease (BD) including ocular BD, but the evidence base is limited, mostly from studies of uveitis and BD manifestations. OBJECTIVE: To review the evidence base for biologics in the treatment of ocular BD. METHODS: Systematic literature search was made using exploded key words-Behçet's, ocular, biologics in MEDLINE, Cochrane library, Database of Abstracts Reviews and Effects, Clinical Trials.gov, Science Direct and Google Scholar. There was no limitation on region, language or date (Search updated 16th October 2018). Literature retrieval was restricted to randomised controlled trials (RCTs) of biologics. RESULTS: Of 237 papers retrieved, eight met the inclusion criteria. RCTs on interferon alpha 2a (INF-α 2a), adalimumab, secukinumab, gevokizumab, rituximab and daclizumab were retrieved (two for adalimumab and gevokizumab). The outcome measures were not met for secukinumab, daclizumab and gevokizumab. Rituximab and INF-α 2a showed promising preliminary results but sufficiently powered RCTs are needed to provide adequate evidence of efficacy. The RCTs on adalimumab did not evaluate efficacy for BD uveitis specifically, hence are of limited value for this review. CONCLUSION: Some biologics show promise in treating BD uveitis, but more RCTs are needed for firm conclusions about efficacy. A phase IV study or, registry of adalimumab could provide data on its efficacy in BD uveitis compared to other forms.
引用
- Uke P, Gorodkin R, Beare N, et al. Biologic therapy for Behçet's uveitis: a systematic review. Br J Ophthalmol. 2019. PMID: 31676596. doi:10.1136/bjophthalmol-2019-314154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。